SE9402370D0 - Use of IGF-I - Google Patents

Use of IGF-I

Info

Publication number
SE9402370D0
SE9402370D0 SE9402370A SE9402370A SE9402370D0 SE 9402370 D0 SE9402370 D0 SE 9402370D0 SE 9402370 A SE9402370 A SE 9402370A SE 9402370 A SE9402370 A SE 9402370A SE 9402370 D0 SE9402370 D0 SE 9402370D0
Authority
SE
Sweden
Prior art keywords
diabetes
subject
high risk
igf
occurrence
Prior art date
Application number
SE9402370A
Other languages
English (en)
Swedish (sv)
Inventor
Charles Thivolet
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9402370A priority Critical patent/SE9402370D0/xx
Publication of SE9402370D0 publication Critical patent/SE9402370D0/xx
Priority to PCT/SE1995/000776 priority patent/WO1996001124A1/fr
Priority to EP95925202A priority patent/EP0759776B1/fr
Priority to DE69528168T priority patent/DE69528168T2/de
Priority to CA002194403A priority patent/CA2194403A1/fr
Priority to AT95925202T priority patent/ATE223729T1/de
Priority to US08/750,733 priority patent/US6342227B1/en
Priority to JP8503824A priority patent/JPH10502367A/ja
Priority to AU29407/95A priority patent/AU689922B2/en
Priority to IL11434395A priority patent/IL114343A0/xx
Priority to US10/050,298 priority patent/US20020132772A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
SE9402370A 1994-07-04 1994-07-04 Use of IGF-I SE9402370D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I
AU29407/95A AU689922B2 (en) 1994-07-04 1995-06-22 Use of IGF-I or analogues thereof in the prevention of diabetes
CA002194403A CA2194403A1 (fr) 1994-07-04 1995-06-22 Utilisation de l'igf-i ou de ses analogues dans la prevention du diabete
EP95925202A EP0759776B1 (fr) 1994-07-04 1995-06-22 Utilisation de l'igf-i ou de ses analogues dans la prevention du diabete
DE69528168T DE69528168T2 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
PCT/SE1995/000776 WO1996001124A1 (fr) 1994-07-04 1995-06-22 Utilisation de l'igf-i ou de ses analogues dans la prevention du diabete
AT95925202T ATE223729T1 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
US08/750,733 US6342227B1 (en) 1994-07-04 1995-06-22 Use of IGF-I or analogues thereof in the prevention of diabetes
JP8503824A JPH10502367A (ja) 1994-07-04 1995-06-22 糖尿病を予防するためのｉｇｆ−ｉ又はその類似体の使用
IL11434395A IL114343A0 (en) 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes
US10/050,298 US20020132772A1 (en) 1994-07-04 2002-01-16 Use of IGF-I or analogues thereof in the prevention of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Publications (1)

Publication Number Publication Date
SE9402370D0 true SE9402370D0 (sv) 1994-07-04

Family

ID=20394633

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Country Status (10)

Country Link
US (2) US6342227B1 (fr)
EP (1) EP0759776B1 (fr)
JP (1) JPH10502367A (fr)
AT (1) ATE223729T1 (fr)
AU (1) AU689922B2 (fr)
CA (1) CA2194403A1 (fr)
DE (1) DE69528168T2 (fr)
IL (1) IL114343A0 (fr)
SE (1) SE9402370D0 (fr)
WO (1) WO1996001124A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
CA2369451C (fr) 1999-04-08 2009-09-22 Genentech, Inc. Composition a base de polypeptides a charge opposee
EP1282437B1 (fr) 2000-05-16 2008-03-19 Genentech, Inc. Traitement des lesions du cartilage
HUP0500733A3 (en) 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2011004051A1 (fr) 2009-07-10 2011-01-13 Universidad Autónoma De Barcelona Compositions de thérapie génique destinées à prévenir et/ou à traiter des maladies auto-immunes
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (fr) 1983-04-25 2002-07-03 Chiron Corporation Synthèse à l'aide d'ADN hybride de facteurs de croissance mûrs du type insuline
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1

Also Published As

Publication number Publication date
AU689922B2 (en) 1998-04-09
ATE223729T1 (de) 2002-09-15
JPH10502367A (ja) 1998-03-03
EP0759776A1 (fr) 1997-03-05
IL114343A0 (en) 1995-10-31
WO1996001124A1 (fr) 1996-01-18
DE69528168D1 (de) 2002-10-17
DE69528168T2 (de) 2003-01-09
CA2194403A1 (fr) 1996-01-18
AU2940795A (en) 1996-01-25
US20020132772A1 (en) 2002-09-19
US6342227B1 (en) 2002-01-29
EP0759776B1 (fr) 2002-09-11

Similar Documents

Publication Publication Date Title
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
DE69723230D1 (de) Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
NO854182L (no) Feste med flere frihetsgrader.
SE9402370D0 (sv) Use of IGF-I
DE68920223D1 (de) Enzymelektroden und ihre Herstellung.
DE3867837D1 (de) Eingangs-/ausgangsarchitektur fuer ringverbundene verteilte-speicher-parallelrechner.
DE3684542D1 (de) Acylcarnitine als absorptionsbeschleuniger fuer die wirkstoffverabreichung ueber die schleimhaeute der nasen-, mund-, sublingual- und vaginalhoehle.
IT8423086A0 (it) Composizione farmaceutica o dietetica ad elevata attivita'antitrombotica e antiarteriosclerotica.
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
IT1185522B (it) Soluzione oftalmica ad azione antiinfiammatoria
IT7928417A0 (it) Composizioni farmaceutiche con esaltazione dell'attivita'terapeutica di cortisonici.
JPS5388761A (en) Electronic watch with auxiliary battery
IT8022925A0 (it) Composizioni di gomma siliconica ad un componente, vulcanizzabili atemperatura ambiente e stabili all'immagazzinamento.
IT8348747A0 (it) Derivati amminometil-benzenici eteroaril-sostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni farmaceutiche che li contengono
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
DK472584A (da) Mikroindkapslet medikament i konfekturematrix
DE3784388T2 (de) Fluessigkristallzelle.
IT8419681A0 (it) Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
DK399985D0 (da) 6-substituerede mitomycin-analoge, deres anvendelse inden for medicinen og kompositioner indeholdende forbindelserne
DE3862846D1 (de) Dehnschraube mit passbund.
AU1956283A (en) 1-(3-(4-(substited aminomethyl)pyrid-2-yl-oxy)-prop-1-yl- amino) - 2-aminocyclobut-i-ene-3,4-diones
JPS52114322A (en) Photographic lens
DK146785A (da) Pharmaceutisk praeparat med indhold af 9alfa, 11beta-dichlor-16alfa-methyl-21-oxycarbonyldicyclohexylmethyloxypregna-1,4-dien-3,20-dion
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.